High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
470.22M
-27.27%
0.051
-355.9%
552.20M
+14.17%
0.052
-12.87%
597.42M
+34.46%
0.056
-156.19%
Estimates Revision
The market is revising Downward the revenue expectations for Evolent Health, Inc. (EVH) for FY2025, with the revenue forecasts being adjusted by -0.34% over the past three months. During the same period, the stock price has changed by -58.27%.
Revenue Estimates for FY2025
Revise Downward
-0.34%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
-71.3%
In Past 3 Month
Stock Price
Go Down
-58.27%
In Past 3 Month
14 Analyst Rating
Wall Street analysts forecast EVH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EVH is 10.79 USD with a low forecast of 7.00 USD and a high forecast of 18.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
14 Buy
0 Hold
0 Sell
Strong Buy
Current: 4.010
Low
7.00
Averages
10.79
High
18.00
Current: 4.010
Low
7.00
Averages
10.79
High
18.00
Citi
Buy
downgrade
2025-11-21
Reason
Citi
Price Target
2025-11-21
downgrade
Buy
Reason
Citi lowered the firm's price target on Evolent Health to $9.50 from $11.50 and keeps a Buy rating on the shares.
JPMorgan
Overweight -> NULL
downgrade
$13 -> $7
2025-11-17
Reason
JPMorgan
Price Target
$13 -> $7
2025-11-17
downgrade
Overweight -> NULL
Reason
JPMorgan lowered the firm's price target on Evolent Health to $7 from $13 and keeps an Overweight rating on the shares. The firm updated the company's model.
Canaccord
Buy
downgrade
$16 -> $9
2025-11-14
Reason
Canaccord
Price Target
$16 -> $9
2025-11-14
downgrade
Buy
Reason
Canaccord lowered the firm's price target on Evolent Health to $9 from $16 and keeps a Buy rating on the shares. The firm lowered its target by removing the premium valuation it had previously as the uncertainty on how ACA open enrollment will turn out as the shutdown ends without action on extending enhanced subsidies has put shares in limbo until more clarity emerges once open enrollment is completed. This and uncertainty on MA and Medicaid membership changes are holding the stock hostage near-term and overshadowing longer-term reasons to invest in Evolent.
Evolent Health
Stephens
Equal Weight -> Overweight
upgrade
$7
2025-11-13
Reason
Evolent Health
Stephens
Price Target
$7
2025-11-13
upgrade
Equal Weight -> Overweight
Reason
Stephens upgraded Evolent Health to Overweight from Equal Weight with an unchanged price target of $7.
Stephens
Stephens
Equal Weight
to
Overweight
upgrade
$7
2025-11-13
Reason
Stephens
Stephens
Price Target
$7
2025-11-13
upgrade
Equal Weight
to
Overweight
Reason
As previously reported, Stephens upgraded Evolent Health to Overweight from Equal Weight with an unchanged price target of $7 after Q3 beat expectations. The firm thought the print was enough for stabilization given already weak sentiment, but fears over 2026 uncertainty weighed on shares and the subsequent end of the government shutdown without a subsidy extension has confirmed what Evolent was already baking into 2026 expectations, the analyst tells investors. The firm contends that sentiment is at or near the bottom, the business is in "a better spot fundamentally than it was a year ago, or even at the start of this year," and that the growth opportunity set is "better than it has been in several years."
Oppenheimer
Oppenheimer
Outperform
to
NULL
downgrade
$18 -> $12
2025-11-12
Reason
Oppenheimer
Oppenheimer
Price Target
$18 -> $12
2025-11-12
downgrade
Outperform
to
NULL
Reason
Oppenheimer lowered the firm's price target on Evolent Health to $12 from $18 and keeps an Outperform rating on the shares following quarterly results. Management provided visibility into 2026 revenue of $2.5B, which reflects $550M of new contract impact. Though the company continues to boast an attractive pipeline of growth, the near-term outlook remains subjected to the uncertainty around Medicare Advantage and the ACA, adds Oppenheimer.
See All Ratings
Valuation Metrics
The current forward P/E ratio for Evolent Health Inc (EVH.N) is 16.92, compared to its 5-year average forward P/E of 26.13. For a more detailed relative valuation and DCF analysis to assess Evolent Health Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
26.13
Current PE
16.92
Overvalued PE
293.19
Undervalued PE
-240.92
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
21.22
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
29.90
Undervalued EV/EBITDA
12.54
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
1.44
Current PS
0.00
Overvalued PS
2.07
Undervalued PS
0.81
Financials
Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
EVH News & Events
Events Timeline
(ET)
2025-11-06
16:32:26
Evolent Health projects FY25 revenue between $1.87B and $1.88B, matching consensus estimate of $1.87B
2025-11-06
16:31:27
Evolent Health projects Q4 revenue between $462M and $472M, slightly below consensus of $472.55M.
2025-11-06
16:30:00
Evolent Health announces Q3 adjusted EPS of 5 cents, falling short of consensus estimate of 10 cents.
Sign Up For More Events
Sign Up For More Events
News
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/cover_image/357bc60d8cd77ef16dd761e0211080de89e8b06cd3f6c27c69f6cacde3f611f2.jpg)
Preview
4.0
11-22BenzingaCitigroup Reaffirms Buy Rating on Evolent Health, Adjusts Price Target to $9.5
Preview
6.0
11-15BenzingaCanaccord Genuity Keeps Buy Rating on Evolent Health, Reduces Price Target to $9
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/cover_image/e0e3aec24cabc994f3dc796ec59fce0271f9c8a09e20919d93e2c9291d3233fb.png)
Preview
3.5
11-11GlobenewswireGlobal Digital Health Market Expected to Hit $1.5 Trillion by 2032 Driven by Advancements in A.I. Technology
Sign Up For More News
People Also Watch
FAQ
What is Evolent Health Inc (EVH) stock price today?
What is Evolent Health Inc (EVH)'s business?
What is the price predicton of EVH Stock?
What is Evolent Health Inc (EVH)'s revenue for the last quarter?
What is Evolent Health Inc (EVH)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Evolent Health Inc (EVH)'s fundamentals?
How many employees does Evolent Health Inc (EVH). have?